Your browser doesn't support javascript.
loading
Progressive Multifocal Leukoencephalopathy and Systemic Lupus Erythematosus: Focus on Etiology.
Berntsson, Shala Ghaderi; Katsarogiannis, Evangelos; Lourenço, Filipa; Moraes-Fontes, Maria Francisca.
Affiliation
  • Berntsson SG; Departments of Neuroscience, Uppsala University Hospital, Uppsala, Sweden; Neurology, Uppsala University Hospital, Uppsala, Sweden.
  • Katsarogiannis E; Departments of Neuroscience, Uppsala University Hospital, Uppsala, Sweden; Neurology, Uppsala University Hospital, Uppsala, Sweden.
  • Lourenço F; Unidade de Doenças Auto-imunes/Serviço Medicina 7.2, Hospital Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal.
  • Moraes-Fontes MF; Unidade de Doenças Auto-imunes/Serviço Medicina 7.2, Hospital Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal.
Case Rep Neurol ; 8(1): 59-65, 2016.
Article in En | MEDLINE | ID: mdl-27065427
ABSTRACT
Progressive multifocal leukoencephalopathy (PML) caused by reactivation of the JC virus (JCV), a human polyomavirus, occurs in autoimmune disorders, most frequently in systemic lupus erythematosus (SLE). We describe a HIV-negative 34-year-old female with SLE who had been treated with immunosuppressant therapy (IST; steroids and azathioprine) since 2004. In 2011, she developed decreased sensation and weakness of the right hand, followed by vertigo and gait instability. The diagnosis of PML was made on the basis of brain MRI findings (posterior fossa lesions) and JCV isolation from the cerebrospinal fluid (700 copies/ml). IST was immediately discontinued. Cidofovir, mirtazapine, mefloquine and cycles of cytarabine were sequentially added, but there was progressive deterioration with a fatal outcome 1 year after disease onset. This report discusses current therapeutic choices for PML and the importance of early infection screening when SLE patients present with neurological symptoms. In the light of recent reports of PML in SLE patients treated with rituximab or belimumab, we highlight that other IST may just as well be implicated. We conclude that severe lymphopenia was most likely responsible for JCV reactivation in this patient and discuss how effective management of lymphopenia in SLE and PML therapy remains an unmet need.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies Language: En Journal: Case Rep Neurol Year: 2016 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies Language: En Journal: Case Rep Neurol Year: 2016 Document type: Article Affiliation country: